|
|
Advertisement
|
|
SIO Announces Third Site Approved for Enrollment in TRIBUTE Trial
Washington, DC (8 October 2025) – The Society of Interventional Oncology (SIO) proudly announces that University of California, San Diego (UCSD) Health and Moores Cancer Center, in San Diego, CA, USA, is the third site approved and activated for enrollment in the society's clinical trial, TRIBUTE: A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy. Anthony Tadros, MD, will serve as the interventional radiology site principal investigator (PI) and Kathryn Tringale, MD, will serve as the radiation oncology site PI.
The TRIBUTE study clinical leadership includes Jack Jennings, MD, PhD, and Clifford Robinson, MD, at Washington University School of Medicine in St. Louis, and Sean Tutton, MD, and James Urbanic, MD, at UCSD. “We are thrilled that UCSD has been activated as the third site in the TRIBUTE Trial since July and is now ready to begin patient enrollment,” said Jennings. “This milestone reflects strong momentum, and we're eager to see additional U.S. sites come online throughout the rest of the year."
The TRIBUTE study is collectively supported by the study's Exclusive Pioneer Trial Partner, Varian, a Siemens Healthineers Company
, the study's Catalyst Trial Partner, Stryker, Inc., and the study's Advocate Trial Partner, Boston Scientific Corporation.
This is the first prospective, multi-center study to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in adult patients treated with both percutaneous ablation and palliative radiation therapy (RT) for symptomatic, high-risk metastatic bone lesions. The study was collaboratively designed and developed with the partnership of radiation oncology, which SIO sees as a critical multidisciplinary partner to the success of the study. Upon completion, the study will enroll 120 subjects from across sites in the United States.
Percutaneous ablation and RT have different mechanisms of alleviating pain and causing tumor death that may work synergistically. Radiation therapy is a widely accepted treatment for painful bone metastases and provides palliation of pain for patients. Percutaneous ablation, a minimally invasive therapy for painful metastatic bone disease, can be performed with thermal modalities (e.g., radiofrequency, microwave, cryoablation) and requires minimal recovery.
|
Advertisement
|
|
It's Time to Renew Your SIO Membership
Stay connected, stay inspired, and stay ahead — it's time to secure your SIO membership for another year! Renewing keeps you connected to exclusive resources and research, educational opportunities, and a community that empowers your growth and impact in the field of interventional oncology (IO). Renew your membership by 31 December 2025 and keep enjoying all the exclusive benefits SIO offers.
Follow the steps below to renew your membership now.
- Log in to your SIO Member Portal
- Select "Membership" on the right-hand side of your profile
- Click "Renew SIO Membership"
Renew Today
Need assistance with your membership? Please visit our FAQ page or contact info@sio-central.org for help troubleshooting.
Find-a-Doctor Directory
Coming this fall! This new directory will help patients find interventional oncologists by disease state and location — and only active SIO members will be listed
|
|
Big Ideas, Bold Science, Beautiful Savannah
Elevate your expertise in Savannah, Georgia, USA, 4–8 February, at the SIO 2026 Annual Scientific Meeting. Experience bold science, innovative education, and hands-on training that will elevate your practice and expand the future of interventional oncology.
Registration is open — secure your spot today.
Register Here
Expanded y90 Dosimetry Hands-on Workshop
Elevate your expertise with four hours of immersive y90 dosimetry training with leading experts at the SIO 2026 Annual Scientific Meeting.
The expanded y90 Dosimetry Hands-on Workshop, held on Friday, 6 February, is designed to sharpen your skills and expand your confidence in radiation dosimetry.
To register, add the y90 Dosimetry Hands-on Workshop to your SIO 2026 Annual Scientific Meeting registration during the checkout process.
An additional fee is required to register for this workshop. Limited seats are available.
What to Expect
Led by an esteemed faculty of interventional oncology experts, this workshop combines expert-led lectures with interactive, case-based learning. You’ll gain practical training in:
- Fundamentals of radiation dosimetry
- Current guidelines and best practices
- Approaches tailored by tumor type, treatment goals, and spheres' type and distribution
For more information, a breakdown of lecture topics, and to view the expert faculty leading each session, please visit our website.
New in 2026: Palliative Pain in Cancer Patients Master Class
Separate Registration Required
New in 2026, on Wednesday, 4 February, in Savannah, the Palliative Pain in Cancer Patients Master Class will transform how you approach cancer-related pain. Through real cases, advanced techniques, and expert-led hands-on training, this half-day program gives you practical skills you can apply immediately.
Learn More
The RISE Forum
Separate Registration Required
Be part of the inaugural RISE Forum: Research, Innovation & Science Exchange on Wednesday, 4 February in Savannah.
SIO is also offering the brand-new RISE Forum Scholarship, open to students, trainees, and early-career researchers passionate about IO. Selected recipients will be invited by 20 October 2025. The application period is now closed.
Learn More
|
Advertisement
|
Promoted by Medtronic
Outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System from the OPuS One trial were recently published in the November edition of the Journal of Vascular and Interventional Radiology (JVIR). Learn more about the largest prospective study in radiofrequency ablation for bone metastases. Learn More
|
|
New Podcast Series Launching This October
Get ready for "Meet the Data," a four-part podcast series exploring pivotal trials that shaped immunotherapy for advanced HCC, supported by an educational grant from AstraZeneca. Releasing in October, this expert-led series brings insights straight from the frontlines of interventional oncology. Stay tuned for more details!
|
Save the Date
SIO is honored to announce the inaugural IO Awareness Week, taking place 25-31 October 2025.
This dedicated week is an annual campaign to increase awareness of the field of interventional oncology and the benefits of IO therapies for cancer patients.
As a member of the SIO community, you understand the vital importance of interventional oncology, and the dedication needed to continue advancing the practice as the fourth pillar of cancer care. IO Awareness Week will serve to help make IO a household name, while providing valuable resources to our community.
We are beyond excited to spread the word of IO, and we hope you will join us in celebrating the first-ever IO Awareness Week. Visit our brand-new website to learn more!
|
|
Ready to Learn? Register for Our Upcoming Webinars
Mark your calendars for our October webinars! Be sure to visit the "Upcoming Webinars" section on our website to view the full schedule and reserve your spot.
Missed a Session? Catch up anytime — previous webinars in this series are available on our On-Demand page.
View On-Demand Webinars
HCC Webinar Series Part 2: Integrating Immunotherapy with Locoregional Therapies in HCC: Mechanisms, Biomarkers, and Resistance
Wednesday, 22 October 2025 | 7 – 8 p.m. ET
Register Here
Webinar Series Sponsored By
Bone Club Series Part 3: How I Do It—From Imaging Workup to Intervention: Cryoneurolysis for Pain
Tuesday, 11 November 2025 | 7 – 8:30 p.m. ET
Register Now
Webinar Series Sponsored By:
|
|
IO Insights
The Society of Interventional Oncology
2001 K Street NW, 3rd Floor North | Washington, DC 20006 USA
202-367-1164 | Contact Us
www.sio-central.org
|
|
|
|
|
|